[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophagogastroduodensocopy-egd-procedure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophagogastroduodensocopy-egd-procedure":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":39,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":5},"100611785","phase-2-premedication-with-n-acetylcysteine-and-simethicone-to-improve-mucosal-visualization-in-elective-upper-endoscopy-100611785",false,"NCT07245095","Premedication With N-acetylcysteine and Simethicone to Improve Mucosal Visualization in Elective Upper Endoscopy","Randomized Controlled Trial to Evaluate the Effect of Premedication With N-acetylcysteine and Simethicone on Mucosal Visibility During Elective Upper Gastrointestinal Endoscopy Using the TUGS Score","NACSIMET","Inclusion Criteria:\n\n* Men and women aged 18 to 70 years old.\n* Patients who agree to participate in the clinical trial.\n* Patients without active gastrointestinal bleeding.\n* Signing of informed consent form.\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity to N-acetylcysteine\n* Patients with a history of hypersensitivity to simethicone\n* Patients with a previous endoscopic diagnosis\n* Patients with a history of gastric or bariatric surgery\n* Patients with a history of motor disorders (e.g., scleroderma, diabetic gastroparesis)\n* Patients taking medications that delay gastric emptying (GLP-1 analogues)\n* Pregnant or breastfeeding patients\n* Patients who do not agree to participate in the clinical trial",true,"ALL","18 Years","99 Years",{"count":22,"type":23},132,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this randomized, double-blind, placebo-controlled clinical trial is to assess whether the combination of N-acetylcysteine and simethicone improves mucosal visibility during upper gastrointestinal endoscopy in adults aged 18 to 99 years of both sexes, including both healthy individuals and those with non-bleeding gastrointestinal symptoms.\n\nThe main questions this study aims to answer are:\n\nDoes pre-endoscopy administration of N-acetylcysteine\u002Fsimethicone improve mucosal visualization based on the Toronto Upper Gastrointestinal Cleanliness Score (TUGS)?\n\nIs this combination safe and well tolerated in this patient population?\n\nResearchers will compare patients receiving N-acetylcysteine (600 mg) and simethicone (100 mg) orally 20-60 minutes before the procedure with those receiving placebo (water) to determine if there is a significant improvement in TUGS scores.\n\nParticipants will:\n\nReceive a single oral dose of either N-acetylcysteine\u002Fsimethicone or placebo prior to endoscopy\n\nUndergo a routine upper GI endoscopy\n\nHave mucosal cleanliness evaluated using the TUGS scoring system\n\nBe monitored for any adverse events or intolerance",[29,30,31,32,33,34,35,36,37,38],"Esophagogastroduodenoscopy","Simethicone","N-Acetylcysteine","Premedication","Visualization","Esophagogastroduodensocopy (EGD) Procedure","Placebo - Control","Gastritis Associated With Helicobacter Pylori","Tumor Gastric","Lesions in the Esophagus, Stomach, Duodenum or Rectum",[29,40,32,30,41,42],"Mucous Membrane","Acetylcysteine","Gastrointestinal Tract","RECRUITING","2025-11-20",{"date":46,"type":47},"2025-11-24","ACTUAL",{"date":49,"type":47},"2025-09-12",{"date":51,"type":23},"2026-12-31",{"name":53,"class":54},"Hospital General de Mexicali","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100572133","phase-4-ondansetron-combined-with-dyclonine-hydrochloride-to-improve-patient-experience-in-unsedated-esophagogastro-duodenoscopy-100572133","NCT06729307","Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopy","Inclusion Criteria:\n\n* Patients indicated for diagnostic EGD: patients with symptoms in which EGD may influence di-agnosis and\u002For disease management, including dysphagia, odynophagia, esophageal refluc symptoms, persistent vomiting, gastrointestinal bleeding, and other upper gastrointestinal symptoms.\n* Signing a written informed consent.\n\nExclusion Criteria:\n\n* Contraindications for esophagogastroduodenoscopy.\n* History of upper gastrointestinal tract surgery.\n* Severe diseases of the heart, kidney, respiratory system, central nervous system, and hematopoietic system.\n* Pregnancy.\n* Neuropsychiatric disorders, severe depression and severe anxiety.\n* Allergy to ondansetron or dyclonine hydrochloride.","45 Years",{"count":63,"type":23},260,[65],"PHASE4","The goal of this clinical trial is to learn if administering ondansetron prior to esophagogastroduodenoscopy (EGD) can alleviate the gagging reflex, nausea and vomiting in Chinese patients undergoing unsedated diagnostic EGD. The main questions it aims to answer are:\n\nDoes taking ondansetron prior to EGD reduce the discomfort of patients during the endoscopic process? Does taking ondansetron prior to EGD reduce the intensity of patient gagging and nausea, and the incidence of vomiting ? Researchers will compare premedication of oral ondasetron and topical pharyngeal anesthesia (dyclonine hydrochloride mucilage) with topical pharyngeal anesthesia only to see if ondansetron can exert the above-mentioned effects.\n\nParticipants will be treated with one of the following regimens according to the randomization result:\n\n* Oral ondansetron of 8 mg 2 hours prior to endoscopic process and dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to endoscopic process;\n* dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to endoscopic process.\n\nAfter the endoscopic process is finished, patients will be asked to fill in a questionnaire that contains the following items, all measured by NRS 0-10:\n\n* Overall discomfort;\n* Intensity of gagging;\n* Willingness to undergo unsedated EGD again if indicated.",[34],"NOT_YET_RECRUITING","2024-12-06",{"date":71,"type":47},"2024-12-11",{"date":73,"type":23},"2025-01",{"date":75,"type":23},"2026-01",{"name":77,"class":54},"Peking Union Medical College Hospital"]